EAACI Congress 2024
BackMastocytosis and mast cells
Sunday 02 Jun, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
1064-nm Q-switched Nd: YAG laser with low-level laser therapy inhibits mast cell activation
12:00
Accuracy of non-invasive diagnostics in hymenoptera venom allergy
12:00
Clinical Evaluation of Allergic Diseases in Pediatric Patients Diagnosed with Cutaneous Mastocytosis: A Retrospective Study
12:00
Healthcare Provider Perspectives on Management of European Patients with Systemic Mastocytosis
12:00
IL-4, TSLP, IL-31 cytokine profile in patients with cognitive disfunctions in systemic mastocytosis
12:00
Inhibition of Skin Mast Cell Degranulation by MRGPRX2 Small Molecule Antagonists
12:00
Investigation of Sleep Disorders by Polysomnography in Patients with Systemic Mastocytosis
12:00
Mastocytosis with skin involvement due to a 6bp insertion in frame in cKIT, responding to imatinib
12:00
Novel KIT Mutation, D816_N819delinsll, in a Patient with Systemic Mastocytosis: A Case Report
12:00
Presence of CD25+ mast cells in gastrointestinal biopsies of patients with systemic mastocytosis and gastrointestinal symptoms
12:00
Prevalence of Genetic Diamine Oxidase (DAO) deficiency in patients with systemic mastocytosis in Romania
12:00
SPOTLIGHT: A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment with H1-Antihis
12:00
Targeting the JAK/STAT pathway with JAK2-selective inhibitors, but not JAK1-selective or JAK1/2 inhibitors, reduces proliferation and induces apoptosis in human neoplastic mast cells
12:00
Unprocessed bovine milk reduces IgE mediated mast cell degranulation and cytokine-induced IL-8 production by intestinal epithelial cells
